...
首页> 外文期刊>Frontiers in Bioengineering and Biotechnology >TREATMENT OF SEVERE STEROID-REFRACTORY ACUTE-GRAFT VERSUS-HOST DISEASE WITH MESENCHYMAL STEM CELLS – SINGLE CENTER EXPERIENCE
【24h】

TREATMENT OF SEVERE STEROID-REFRACTORY ACUTE-GRAFT VERSUS-HOST DISEASE WITH MESENCHYMAL STEM CELLS – SINGLE CENTER EXPERIENCE

机译:间充质干细胞治疗严重的耐激素性急性移植物抗宿主病–单中心经验

获取原文

摘要

The most effective treatment of steroid refractory acute graft versus host disease (aGvHD) is not yet established and mesenchymal stem cells (MSC) appear to be a promising therapy for the condition. We report single center case series of three patients, who underwent allogeneic hematopoietic cell transplantation and later developed steroid refractory graft-versus-host disease, treated with MSC infusions. Two patients achieved complete remission and one patient partial remission of skin and/or gastrointestinal aGvHD. We demonstrated application of MSC for treatment of severe steroid refractory aGvHD is feasible in clinical practice. Detailed description of patient’s features and MSC production protocol is crucial for future comparison on efficacy and safety of cell-based therapies. However, for any substantial conclusions regarding efficacy of MSC higher patient numbers will be required.
机译:尚未确定最有效的治疗类固醇难治性急性移植物抗宿主病的方法,间充质干细胞(MSC)似乎是一种有希望的治疗方法。我们报告了三例患者的单中心病例系列,他们接受了同种异体造血细胞移植,后来发展为类固醇难治性移植物抗宿主病,接受了MSC输注治疗。两名患者的皮肤和/或胃肠道aGvHD完全缓解,一名患者部分缓解。我们证明了将MSC用于治疗严重的类固醇难治性aGvHD在临床实践中是可行的。对患者特征和MSC生产方案的详细描述对于将来基于细胞疗法的疗效和安全性比较至关重要。但是,对于有关MSC疗效的任何实质性结论,将需要更高的患者人数。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号